Efficacy of Interferon Treatment for Chronic Hepatitis C Predicted by Feature Subset Selection and Support Vector Machine
- 61 Downloads
Chronic hepatitis C is a disease that is difficult to treat. At present, interferon might be the only drug, which can cure this kind of disease, but its efficacy is limited and patients face the risk of side effects and high expense, so doctors considering interferon must make a serious choice. The purpose of this study is to establish a simple model and use the clinical data to predict the interferon efficacy. This model is a combination of Feature Subset Selection and the Classifier using a Support Vector Machine (SVM). The study indicates that when five features have been selected, the identification by the SVM is as follows: the identification rate for the effective group is 85%, and the ineffective group 83%. Analysis of selected features show that HCV-RNA level, hepatobiopsy, HCV genotype, ALP and CHE are the most significant features. The results thus serve for the doctors’ reference when they make decisions regarding interferon treatment.
KeywordsChronic Hepatitis C (CHC) Interferon (IFN) Support Vector Machine (SVM) Feature Subset Selection (FSS) Predict
J.Y and A.S.N contributed equally to this study. The research of A.S.N is partially supported by a Grant-in-Aid for Private University High-Tech Research Center from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
- 7.Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M, Reindollar, R., Goodman, Z. D., Koury, K., Ling, M. H., and Albrecht, J. K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:958–965, 2001.CrossRefGoogle Scholar
- 8.Fried, M. W., Schiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Hãussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., and Yu, J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975–982, 2002.CrossRefGoogle Scholar
- 9.Duda, R. O., Hart, P. E & Stork, D. G. Pattern Classification (2nd ed.). Wiley Interscience. New York, NY, 2000.Google Scholar
- 10.Cristianini, N., and Shawe-Taylor, J. An Introduction to Support Vector Machines (and other kernel-based learning methods). Cambridge University Press. 2000.Google Scholar
- 11.EASL Intemational Consensus Conference on hepatitis C. Paris, 26-28, February 1999 Consensus statement. Journal of Hepatology. 30(5): 956–961, 1999.Google Scholar
- 14.Kanai, K., Kako, M., Aikawa, T., and Kumada, T. Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype. Liver. 15:185–188, 1995.Google Scholar
- 15.Kiyosawa, K. The value of hepatitis C virus genotyping to epidemiological and clinical studies. J. Gastroenterol. Hepatol. 12:623–624, 1997.Google Scholar
- 16.Chayama, K., Tsubota, A., Kobayashi, M., and Okamoto, K. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology. 25:745–749, 1997.CrossRefGoogle Scholar
- 19.Nousbaum, J. B., Pol, S., Naloas, B., and Landais, P. Hepatitis C virus type 1b(II) infection in France and Italy. Ann. Intern. Med. 122:161–168, 1995.Google Scholar
- 25.Bishop, C., M., Neural Networks for Pattern Recognition, Oxford University Press, 1995.Google Scholar
- 27.Hwang, Y., Chen, E. Y., Gu, Z. J., Chuang, W. L., Yu, M. L., Lai, M. Y., Chao, Y. C., Lee, C. M., Wang, J. H., Dai, C. Y., Shian-Jy Bey, M., Liao, Y. T., Chen, P. J., and Chen, D. S. Genetic predisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics. 7(5):697–709, 2006.CrossRefGoogle Scholar